CANDEL THERAPEUTICS, INC. Investment Income, Net
CANDEL THERAPEUTICS, INC. (CADL) reported Investment Income, Net of -$490.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2023-03-30
- CANDEL THERAPEUTICS, INC. investment income, net for the quarter ending 2022-12-31 was $226.00K.
- CANDEL THERAPEUTICS, INC. investment income, net for the quarter ending 2022-09-30 was -$176.00K.
- CANDEL THERAPEUTICS, INC. investment income, net for the quarter ending 2022-06-30 was -$365.00K.
- CANDEL THERAPEUTICS, INC. investment income, net for the quarter ending 2022-03-31 was -$175.00K.
- CANDEL THERAPEUTICS, INC. investment income, net for fiscal 2022 was -$490.00K.
- CANDEL THERAPEUTICS, INC. investment income, net for fiscal 2021 was -$53.00K, a 147.75% decline from fiscal 2020.
- CANDEL THERAPEUTICS, INC. investment income, net for fiscal 2020 was $111.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $50.00K derived: sum of 2 quarters · filed 2023-03-30 | -$315.00K derived: sum of 3 quarters · filed 2023-03-30 | -$490.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | -$176.00K 10-Q · filed 2022-11-10 | -$541.00K derived: sum of 2 quarters · filed 2022-11-10 | -$716.00K 10-Q · filed 2022-11-10 | -$727.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | -$365.00K 10-Q · filed 2022-08-05 | -$540.00K 10-Q · filed 2022-08-05 | -$551.00K derived: sum of 3 quarters · filed 2023-03-30 | -$565.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | -$175.00K 10-Q · filed 2022-05-12 | -$186.00K derived: sum of 2 quarters · filed 2023-03-30 | -$200.00K derived: sum of 3 quarters · filed 2023-03-30 | -$215.00K derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$25.00K derived: sum of 2 quarters · filed 2023-03-30 | -$40.00K derived: sum of 3 quarters · filed 2023-03-30 | -$53.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$14.00K 10-Q · filed 2022-11-10 | -$29.00K derived: sum of 2 quarters · filed 2022-11-10 | -$42.00K 10-Q · filed 2022-11-10 | $8.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$15.00K 10-Q · filed 2022-08-05 | -$28.00K 10-Q · filed 2022-08-05 | $22.00K derived: sum of 3 quarters · filed 2022-08-05 | $63.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$12.00K 10-Q · filed 2022-05-12 | $37.00K derived: sum of 2 quarters · filed 2022-05-12 | $78.00K derived: sum of 3 quarters · filed 2022-05-12 | $172.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $90.00K derived: sum of 2 quarters · filed 2022-03-29 | $184.00K derived: sum of 3 quarters · filed 2022-03-29 | $111.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $41.00K 10-Q · filed 2021-11-12 | $135.00K derived: sum of 2 quarters · filed 2021-11-12 | $62.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $94.00K 10-Q · filed 2021-09-08 | $22.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |